A Look At What Eye See

Eric Lefkofsky- Fortune Recap

Cancer is one of the most feared diseases known to man. According to the National Cancer Institute, over 1,600,000 new cases of cancer were diagnosed just last year. The most common types of cancer continue to be breast, lung, colon, and prostate. With so many people being affected by these diseases each and every year, you would think we would have a lot of data on the topic to prevent future tragedies and suffering. In specific, it would stand to reason that we would have access to detailed cohort information as well as co-existing health issues and medication use that complicate cancer treatment or influence how a patient responds to their prescribed treatment.

While it’s true that we have a moderate amount of data on some of the main causes of cancer, much more is needed if we are to have a positive long-term impact on those suffering. We also are familiar with statistics on survival rates and general prognosis for various types of cancer, but we do not have specific cohort information that could provide valuable insight into how to help future generations of cancer patients.

What is Tempus and What do They Offer Cancer Patients?

Tempus is a technology company created to provide cancer patients and medical professionals the clinical data needed to make treatment diseases more successful. Tempus is building a library of both molecular and clinical data to make this possible.

At the present time, we lack important statistical cohort information regarding those who are or have been treated for cancer in the past. Without this information, we can’t provide targeted assistance to future cancer patients. Therefore, the goal of Tempus is to provide specific information that allows current cancer patients to benefit from the successes failures of cancer patients treated in the past.

For example, if we have a group of women being treated for breast cancer and 60% are responding well while 40% are not, we need to know specific information about this other 40%. Do the women in the group that are not responding well to treatment have other health issues that complicate things? Do the women in this group take other medications that may be preventing good results from treatment? Previously, we have lacked this vital information. If we start gathering this type of statistical data, we will have so much more to offer in terms of benefits for future cancer patients. We will be able to take current cancer treatments and make them even more successful, and we will be able to target specific treatments to certain groups of individuals for which they will work the best, providing a much better outlook and quality of life for these individuals.

Tempus is able to provide genome sequencing and molecular and therapeutic data that allows doctors to make treatment decisions that are targeted to that specific patient’s needs. Their goal is for each patient to benefit from the treatment of others who came before them and they accomplish this by offering medical professionals the tools they need to understand specific treatment worked well for some patients and not others.

Who is Eric Lefkofsky?

Eric Lefkofsky is the co-founder and CEO of Tempus. Mr. Lefkofsky was personally motivated to offer assistance in the world of cancer treatment due to the fact that his own wife suffered from breast cancer. Eric Lefkofsky through his wife’s experience with cancer that Eric realized that we simply do not have access to the kind of data we need to provide the most targeted and successful treatment options for each individual cancer patient. He set out to change this when he co-founded Tempus, designing a way to gather more targeted information on cancer and treatments for the disease. The goal of this information is not to replace what data we do currently have on cancer treatment, but to compliment our current data and take it a step further in offering more personalized treatment options that offer better outcomes for success.

Aside from his involvement in Tempus, Eric Lefkofsky also established the Lefkofsky Family Foundation. The LFF is a private charity he formed alongside his wife that provides many services to enhance the lives of children and families everywhere through arts, education, medical, and human rights endeavors. Mr. Lefkofsky studied at the University of Michigan and also serves as an adjunct professor at the University of Chicago.

Millions of Americans continue to be affected by cancer every year, making it an important topic of discussion and research. While we do have limited data on current cancer treatments and various populations affected by cancer, we need much more in-depth information and statistics in order to target these treatments to specific patients. With this targeted type of personal therapy, we can provide the best treatment options for each patient depending on other aspects of their life and health. By doing so, we can help these patients have the best outcome from their treatment and live a longer, more satisfying life.